Creating an Acquisition’s Next Generation in a Novel Ablation Technology

Ximedica’s team helped Boston Scientific reshape the treatment of menorrhagia, through the redesign of an acquired saline ablation system.


Affecting one in every five women, menorrhagia is an extremely common but debilitating condition. There are a variety of different treatments, including drug therapy, dilatation and curettage, hysterectomy, and endometrial ablation, but each method comes with risks, complications, and potentially low success rates. Existing surgical treatments are inconsistent and invasive, leading to discomfort and long recovery times that prevent the 10 million American patients each year, from returning to their normal lifestyle.


After making a strategic acquisition, Boston Scientific approached Ximedica to create a new generation ablation system with the indication for treating Menorrhagia. The device was clinically viable but difficult to use - it took 78 complex steps to start the device, required constant visual monitoring, and took up a significant amount of physical space in an already crowded clinical setting. To be marketable, the device needed to be more intuitive and have a smaller footprint. Boston Scientific partnered with Ximedica’s vertically integrated product development team to redesign the device from the ground up.

Why Ximedica?

Boston Scientific utilized Ximedica’s expertise in:

  • Precision Fluidics and Fluidic Pressure Controls
  • Thermal Controls
  • Human-Centric Design
  • Design Assurance and Verification
  • Software Engineering
  • Industrial Design
  • Disposable Design